Download Files:
LXE408
$690 – $1,150
Products Details
Product Description
– LXE408 is an orally active, non-competitive and kinetoplastid-selective proteasome inhibitor. LXE408 has an IC50 of 0.04 μM for L. donovani proteasome and an EC50 of 0.04 μM for L. donovani. LXE408 has a low propensity to cross the blood brain barrier. LXE408 has the potential for visceral leishmaniasis (VL) research[1].
Web ID
– HY-131350
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C23H18FN7O2
References
– [1]Advait Nagle, et al. Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases. J Med Chem. 2020 Jul 15.
CAS Number
– 1799330-15-6
Molecular Weight
– 443.43
Compound Purity
– 99.08
SMILES
– O=C(C1=C(C)N=C(C)O1)NC2=CC=C(F)C(C3=NN4C=C(C5=NC=CC=C5C)C=NC4=N3)=C2
Clinical Information
– Phase 2
Research Area
– Infection
Solubility
– DMSO : 16.67 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Parasite;Proteasome
Isoform
– Leishmania
Pathway
– Anti-infection;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
